Evidence map›Paper›PMID 32064171›Full record

ArticleAmerican journal of cancer research2020

Peptides containing the MXXCW motif inhibit oncogenic RET kinase activity with a novel mechanism of action.

Kozue Takeda, Yoshiyuki Kawamoto, Yosuke Nagasaki, Yusuke Okuno, Yuko Goto, Machiko Iida, Ichiro Yajima, Nobutaka Ohgami, Masashi Kato

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kozue TakedaCollege of Life and Health Sciences, Chubu University Kasugai, Aichi, Japan.
Yoshiyuki KawamotoCollege of Life and Health Sciences, Chubu University Kasugai, Aichi, Japan.
Yosuke NagasakiCollege of Life and Health Sciences, Chubu University Kasugai, Aichi, Japan.
Yusuke OkunoMedical Genomics Center, Nagoya University Hospital Nagoya, Japan.
Yuko GotoCollege of Life and Health Sciences, Chubu University Kasugai, Aichi, Japan.
Machiko IidaCollege of Life and Health Sciences, Chubu University Kasugai, Aichi, Japan.
Ichiro YajimaCollege of Life and Health Sciences, Chubu University Kasugai, Aichi, Japan.
Nobutaka OhgamiCollege of Life and Health Sciences, Chubu University Kasugai, Aichi, Japan.
Masashi KatoCollege of Life and Health Sciences, Chubu University Kasugai, Aichi, Japan.
Chubu University · JPNagoya University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

REarranged during Transition (RET) is a tyrosine kinase associated with the development of several malignancies. Identification of RET kinase inhibitors promises valuable therapeutic tools for the intervention of RET-driven tumors. Most currently available tyrosine kinase inhibitors target the ATP binding site, but there are several drawbacks of these ATP-competitive drugs. Therefore, there is a need to develop new kinase inhibitors with alternative mechanisms of action. We have previously reported that a conserved cysteine in the MXXCW motif of RET is crucial to the disulfide-bonded dimerization-linked activation of RET kinases. Reagents which bind to this cysteine may inhibit the activity of RET kinases through disulfide-bond mediated dimerization. Here, we examine the potential of MXXCW motif-containing peptides as candidate kinase inhibitors. We demonstrate that MXXCW motif-containing peptides bind to RET in a redox-sensitive manner and block enzymatic activity, causing inhibition of the RET-dependent activity of extracellular signal-regulated kinases and effectively reducing the malignant potential of RET-papillary thyroid carcinoma-1 (PTC)-expressing cells. These motif-containing peptides were also found to be effective against the drug resistant mutant of RET. The inhibition of RET kinase activity by these peptides resulted in suppression of RET-PTC-1-mediated cancer growth. The great potency of these cysteine targeted peptides could indicate promising approaches for novel molecular-targeted therapies for RET-associated cancers.

Indexed as

cysteinepeptideRETtyrosine kinase inhibitor

Identifiers

PMID32064171
PMCPMC7017734
OpenAlexW3012423139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.